PellePharm
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
101 Mission St Ste 1950, San Francisco, ...Phone Number
(510) 502-6144Website
www.pellepharm.comRevenue
$16.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About PellePharm
PellePharm is a biotechnology company dedicated to addressing rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas, through precision medicine. The company focuses on developing patidegib, an investigational topical treatment aimed at reducing tumor burden in affected patients. Collaborating with organizations like the Gorlin Syndrome Alliance, PellePharm strives to advance research and transform the lives of individuals impacted by these conditions. With a commitment to patient care, PellePharm is working towards providing effective therapies in a field with currently no FDA-approved options.Explore more
PellePharm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PellePharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when PellePharm launches new products
Check if PellePharm has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at PellePharm
Earning: See what the market has to say on PellePharm recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once PellePharm has new funding data
Click to see if PellePharm had a recent Job posting/layoffs
PellePharm, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if PellePharm is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to PellePharm
Compare insights from companies similar to PellePharm, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
PellePharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PellePharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PellePharm.
PellePharm financials insights
Gather financial insights about PellePharm, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$1.3M
2015
Private Equity
$4.5M
Private Equity
$719K
2016
Private Equity
$3.2M
2017
Series B
$20M
2018
Unspecified
$70M
PellePharm Tech Stack
A closer look at the technologies used by PellePharm
PellePharm News & Media
PellePharm to Highlight Clinical Programs at the 29th Congress of the European Academy of Dermatology and Venereology
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, Inc., a BridgeBio Pharma, Inc. company, today announced the presentation of various data highlighting product candidate patidegib topical gel for adults with Gorlin syndrome and high-frequency basal cell carcinoma (HF-BCC). The presentations will be made during the 29th Congress of the European Academy of Dermatology and Venereology (EADV), to be held virtually October 29 – 31, 2020. Patidegib topical gel is in development to reduce the large volume oPellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, Inc., a BridgeBio Pharma, Inc. (Nasdaq: BBIO) company, today announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma (HF-BCC). HF-BCC is a rare disease that causes a higher than average number of BCCs to develop, specifically in the facial area. PellePharm is a late clinical-stage biopharmaceutical company committed to tarPellePharm to Present at Piper Jaffray Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Piper Jaffray Healthcare Conference on Tuesday, November 27, at 12:30 p.m. EST in New York. A live webcast of the presentation can be accessed on the company’s website at www.pellepharm.com. A replay of the webcast will be archivedPellePharm Presents Updated Data from Two Phase 2 Studies Demonstrating the Potential of Patidegib Topical Gel to Treat Basal Cell Carcinomas in Patients with Gorlin Syndrome and in Patients with Non-Gorlin Sporadic BCCs
SAN FRANCISCO--(BUSINESS WIRE)--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare skin conditions at their source, today presented updated clinical data from two Phase 2 studies of patidegib topical gel in a poster session at NORD’s Rare Diseases and Orphan Products Breakthrough Summit 2018 in Washington, D.C. Results of the studies showed clinical clearance and prevention of basal cell carcinoma (BCC) tumors after 6 months of treatment with patidegib topic
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding PellePharm
Sign Up For FreeTo access detailed company insights
PellePharm is a biotechnology company dedicated to addressing rare dermatological diseases, particularly Gorlin Syndrome and Basal Cell Carcinomas, through precision medicine. The company focuses on developing patidegib, an investigational topical treatment aimed at reducing tumor burden in affected patients. Collaborating with organizations like t... Read More
